Background: The objective of this work is to document performance of automated insulin delivery (AID) during real-life use in type 2 diabetes (T2D).
Methods: A retrospective analysis was performed of continuous glucose monitoring and insulin delivery data from 796 individuals with T2D, who transitioned from 1-month predictive low-glucose suspend (PLGS) use to 3-month AID use, in real-life settings. Primary outcome was change of time in range (TIR = 70-180 mg/dL) from PLGS to AID. Secondary outcomes included time above/below range (TAR/TBR) and total daily insulin (TDI).
Results: Compared with PLGS, AID increased TIR on average from 63.2% to 72.6%, decreased TAR from 36.2% to 26.8%, and increased TDI from 70.2 to 76.3 U (all < .001), without significant change to TBR. Glycemic improvements were more pronounced in those with worse glycemic control during PLGS use ( < .001).
Conclusions: Real-life use of AID led to a rapid and sustained improvement of glycemic control in individuals with T2D.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572011 | PMC |
| http://dx.doi.org/10.1177/19322968241274786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
Diabetes Obes Metab
January 2025
Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.
Aims: Women with previous gestational diabetes mellitus (GDM) have an increased risk for later development of type 2 diabetes. During pregnancy, GDM affects the cardio-metabolic protein profile; however, it is unknown how GDM affects the cardio-metabolic protein profile in the long term and if it is associated with type 2 diabetes after GDM. We hypothesise that the cardio-metabolic protein profile is affected long term and is associated with the development of type 2 diabetes after GDM.
View Article and Find Full Text PDFDGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells.
Sci Rep
January 2025
Science For Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
A distinctive feature of both type 1 and type 2 diabetes is the waning of insulin-secreting beta cells in the pancreas. New methods for direct and specific targeting of the beta cells could provide platforms for delivery of pharmaceutical reagents. Imaging techniques such as Positron Emission Tomography (PET) rely on the efficient and specific delivery of imaging reagents, and could greatly improve our understanding of diabetes etiology as well as providing biomarkers for viable beta-cell mass in tissue, in both pancreas and in islet grafts.
View Article and Find Full Text PDFStrategies to Enhance the Therapeutic Efficacy of GLP-1 Receptor Agonists through Structural Modification and Carrier Delivery.
Chembiochem
January 2025
Nankai University, Institute of Polymer Chemistry, CHINA.
Diabetes is a metabolic disorder characterized by insufficient endogenous insulin production or impaired sensitivity to insulin. In recent years, a class of incretin-based hypoglycemic drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), have attracted great attention in the management of type 2 diabetes mellitus (T2DM) due to their benefits, including stable glycemic control ability, a low risk of hypoglycemia, and weight reduction for patients. However, like other peptide drugs, GLP-1RAs face challenges such as instability, susceptibility to enzymatic degradation, and immunogenicity, which severely limit their clinical application.
View Article and Find Full Text PDFA Polysaccharide-Calcium Carbonate Microsphere-Doped Hydrogel for Accelerated Diabetic Wound Healing via Synergistic Glucose-Responsive Hypoglycemic and Anti-Inflammatory Effects.
ACS Biomater Sci Eng
January 2025
Henan International Joint Laboratory of Medicinal Plants Utilization, College of Chemistry and Molecular Sciences, Henan Key Laboratory of Natural Medicine Innovation and Transformation, State Key Laboratory of Antiviral Drugs, Henan University, Kaifeng 475004, China.
As common complications of diabetes, long-term hyperglycemia and inflammatory infiltration often lead to prolonged unhealing of chronic diabetic wounds. The natural hydrogel-containing plant polysaccharides were recorded to have effective hypoglycemic and anti-inflammatory effects. This study focused on the accelerating effect of diabetic wound healing of hydrogels doped with polysaccharide (DOP)─calcium carbonate (CaCO) microspheres, which have glucose-responsive insulin release and anti-inflammatory effects.
View Article and Find Full Text PDFOn-demand release of insulin using glucose-responsive chitosan-based three-compartment microspheres.
Int J Biol Macromol
December 2024
Joint Laboratory of Advanced Biomedical Materials (NFU-UGent), Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China. Electronic address:
Various injectable glucose-responsive insulin release systems, including microspheres, have been developed to achieve insulin release for over a day. However, a major challenge is on-demand release insulin, which is closely related to the degradation rate of the delivery vehicle. Herein, chitosan-based three-compartment microspheres (TCMs) were fabricated using gas-shearing microfluidics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!